141 related articles for article (PubMed ID: 36056582)
1. The WID-qEC test: Performance in a hospital-based cohort and feasibility to detect endometrial and cervical cancers.
Schreiberhuber L; Herzog C; Vavourakis CD; Redl E; Kastner C; Jones A; Evans I; Zikan M; Cibula D; Widschwendter P; Pfau K; Math B; Seewald M; Amory S; Obrist P; Widschwendter M
Int J Cancer; 2023 Mar; 152(6):1269-1274. PubMed ID: 36056582
[TBL] [Abstract][Full Text] [Related]
2. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.
Evans I; Reisel D; Jones A; Bajrami A; Nijjar S; Solangon SA; Arora R; Redl E; Schreiberhuber L; Ishaq-Parveen I; Rothärmel J; Herzog C; Jurkovic D; Widschwendter M
Lancet Oncol; 2023 Dec; 24(12):1375-1386. PubMed ID: 37944542
[TBL] [Abstract][Full Text] [Related]
3. A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
Herzog C; Marín F; Jones A; Evans I; Reisel D; Redl E; Schreiberhuber L; Paytubi S; Pelegrina B; Carmona Á; Peremiquel-Trillas P; Frias-Gomez J; Pineda M; Brunet J; Ponce J; Matias-Guiu X; de Sanjosé S; Alemany L; Olaitan A; Wong M; Jurkovic D; Crosbie EJ; Rosenthal AN; Bjørge L; Zikan M; Dostalek L; Cibula D; Sundström K; Dillner J; Costas L; Widschwendter M
J Clin Oncol; 2022 Nov; 40(33):3828-3838. PubMed ID: 36001862
[TBL] [Abstract][Full Text] [Related]
4. The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer.
Barrett JE; Sundström K; Jones A; Evans I; Wang J; Herzog C; Dillner J; Widschwendter M
Genome Med; 2022 Oct; 14(1):116. PubMed ID: 36258199
[TBL] [Abstract][Full Text] [Related]
5. High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities.
Illah O; Scott M; Redl E; Barrett JE; Schreiberhuber L; Herzog C; Vavourakis CD; Jones A; Evans I; Reisel D; Chandrasekaran D; Doufekas K; Graham R; Kotsopoulos IC; MacDonald N; Arora R; Olaitan A; Rosenthal A; Widschwendter M
Int J Cancer; 2024 May; ():. PubMed ID: 38739012
[TBL] [Abstract][Full Text] [Related]
6. The WID-EC test for the detection and risk prediction of endometrial cancer.
Barrett JE; Jones A; Evans I; Herzog C; Reisel D; Olaitan A; Mould T; MacDonald N; Doufekas K; Newton C; Crosbie EJ; Bjørge L; Colombo N; Dostalek L; Costas L; Peremiquel-Trillas P; Ponce J; Matias-Guiu X; Zikan M; Cibula D; Wang J; Sundström K; Dillner J; Widschwendter M
Int J Cancer; 2023 May; 152(9):1977-1988. PubMed ID: 36533702
[TBL] [Abstract][Full Text] [Related]
7. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
8. Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.
Guerrero-Preston R; Valle BL; Jedlicka A; Turaga N; Folawiyo O; Pirini F; Lawson F; Vergura A; Noordhuis M; Dziedzic A; Pérez G; Renehan M; Guerrero-Diaz C; De Jesus Rodríguez E; Diaz-Montes T; Rodríguez Orengo J; Méndez K; Romaguera J; Trock BJ; Florea L; Sidransky D
Cancer Prev Res (Phila); 2016 Dec; 9(12):915-924. PubMed ID: 27671338
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation analysis in liquid-based cytology for cervical cancer screening.
Apostolidou S; Hadwin R; Burnell M; Jones A; Baff D; Pyndiah N; Mould T; Jacobs IJ; Beddows S; Kocjan G; Widschwendter M
Int J Cancer; 2009 Dec; 125(12):2995-3002. PubMed ID: 19609949
[TBL] [Abstract][Full Text] [Related]
12. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
[TBL] [Abstract][Full Text] [Related]
13. Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates.
Rozemeijer K; Penning C; Siebers AG; Naber SK; Matthijsse SM; van Ballegooijen M; van Kemenade FJ; de Kok IM
Cancer Causes Control; 2016 Jan; 27(1):15-25. PubMed ID: 26458884
[TBL] [Abstract][Full Text] [Related]
14. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
15. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
16. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
17. [A study of cervical cancer screening algorithms].
Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of abnormal cervical cytology by liquid based cytology in the antenatal care clinic, Thammasat University Hospital.
Khaengkhor P; Mairaing K; Suwannarurk K; Thaweekul Y; Poomtavorn Y; Pattaraarchachai J; Bhamarapravatana K
J Med Assoc Thai; 2011 Feb; 94(2):152-8. PubMed ID: 21534360
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
